| Patient cohort | Patient subgroup for serum analysis* | ||
---|---|---|---|---|
 | (n = 125) | (n = 70) | ||
 | tTP high | tTP low | sTP high | sTP low |
Age (year) | Â | Â | Â | Â |
  Median (IQR) | 68 (59–75) | 64 (57–73) | 66 (56–75) | 65 (59–74) |
Gender (%) | Â | Â | Â | Â |
  Female | 27 (44) | 31 (49) | 15 (43) | 12 (34) |
  Male | 35 (56) | 32 (51) | 20 (57) | 23 (66) |
Tumour location (%) | Â | Â | Â | Â |
  Colon | 26 (42) | 43 (68) | 21 (60) | 18 (51) |
  Rectum | 36 (58) | 20 (32) | 14 (40) | 17 (49) |
Tumour stage (%) | Â | Â | Â | Â |
  I | 4 (6) | - | 1 (3) | - |
  II | 17 (27) | 4 (6) | 6 (17) | 6 (17) |
  III | 24 (39) | 27 (43) | 12 (34) | 16 (46) |
  IV | 17 (27) | 32 (51) | 16 (46) | 13 (37) |
Tumour differentiation (%) | Â | Â | Â | Â |
  Well | 1 (2) | 1 (2) | - | 1 (3) |
  Medium | 42 (68) | 36 (57) | 23 (66) | 23 (66) |
  Poor | 16 (26) | 20 (32) | 9 (26) | 8 (23) |
  Mucinous | 2 (3) | 6 (10) | 3 (9) | 3 (8) |
  Unknown | 1 (2) | - | - | - |
Assessed lymph nodes, median (IQR) | 17 (12–24) | 19 (16–25) | 17 (14–26) | 21 (14–29) |
Positive lymph nodes, median (IQR) | 1 (0–6) | 4 (2–8) | 3 (0–8) | 3 (1–9) |
T-stage (%) | Â | Â | Â | Â |
  1 | - | - | - | - |
  2 | 8 (13) | - | 2 (6) | 2 (6) |
  3 | 36 (58) | 32 (51) | 16 (46) | 19 (54) |
  4 | 13 (21) | 25 (40) | 15 (43) | 14 (40) |
Not evaluable | 5 (8) | 6 (10) | 2 (6) | - |
N-stage (%)†‡ |  |  |  |  |
  0 | 25 (40) | 6 (10) | 9 (26) | 8 (23) |
  1a | 8 (13) | 9 (14) | 6 (17) | 5 (14) |
  1b | 6 (10) | 11 (17) | 2 (6) | 5 (14) |
  2a | 9 (14) | 15 (24) | 7 (20) | 5 (14) |
  2b | 13 (21) | 22 (35) | 10 (28) | 12 (34) |
  X | 1 (2) | - | 1 (3) | - |
Metastatic sites (%) | Â | Â | Â | Â |
  Liver | 24 (39) | 27 (43) | 13 (37) | 19 (549 |
  Pulmonary | 3 (5) | 3 (5) | 1 (3) | 2 (6) |
  Skeletal | - | 1 (2) | - | - |
  Local | 3 (5) | 2 (3) | 3 (9) | - |
  Multiple including liver | 19 (31) | 17 (27) | 13 (37) | 5 (14) |
  Multiple excluding liver | 8 (13) | 10 (16) | 4 (11) | 4 (11) |
  Lymphatic | 5 (8) | 3 (5) | 1 (3) | 5 (14) |